Can iron metabolism matter not only for the liver, heart or pancreas, but also for the kidneys? A new paper published in 2026 in the journal Renal Failure suggests that iron metabolism disorders may be linked to the risk of kidney stones. This is a topic of particular interest to people with hemochromatosis, although it must be emphasised from the outset: the study did not directly involve patients with hemochromatosis and does not prove that excess iron independently causes kidney stones.
Why is this study interesting?
The authors asked whether abnormal iron metabolism might also be associated with kidney stones. Kidney stones are a common urological problem, have a strong tendency to recur, and are linked, among other things, to oxidative stress and damage to the kidney tubule epithelium.
Iron is an element essential to life, but in excess it can intensify the production of reactive oxygen species. It is precisely this mechanism that makes excess free or improperly distributed iron potentially toxic to cells.
How was the study conducted?
The work had two parts.
The first was an epidemiological analysis of data from the American population study NHANES 2017–2018. A total of 4,370 adult participants were included. Researchers examined whether selected iron metabolism markers were associated with a history of kidney stones.
Parameters analysed included:
- ferritin,
- serum iron,
- transferrin saturation — TSAT,
- soluble transferrin receptor — sTfR,
- haemoglobin,
- mean corpuscular haemoglobin content,
- daily iron intake from diet and supplements.
The second part of the study was experimental. The authors used a mouse model of kidney stones to examine whether iron accumulation, oxidative stress and activation of processes related to so-called ferroptosis occur in the kidneys of stone-forming animals.
Key findings from the population analysis
In the analysed population, approximately 10.6% of adults had a history of kidney stones. People with kidney stones were on average older, had higher BMI and a higher inflammatory index SIRI.
The most interesting results concerned three iron metabolism parameters:
1. Lower transferrin saturation was associated with a higher risk of kidney stones
In the fully adjusted statistical model, every 10% higher transferrin saturation was associated with a 26% lower likelihood of kidney stones.
In simple terms: people with lower TSAT more often reported kidney stones.
This is interesting because low TSAT is usually associated with iron unavailability to tissues rather than iron excess. However, the authors suggest this may involve a more complex phenomenon: a relative iron deficit in the circulation alongside local iron accumulation in the kidneys.
2. Higher iron intake was associated with a higher risk of kidney stones
Each additional 10 mg of iron per day from diet and supplements was associated with a 12% higher likelihood of kidney stones.
Importantly, the relationship was not entirely linear. The analysis indicated a U-shaped pattern. The lowest risk was observed at an intake of approximately 11.7 mg of iron per day. Below this value, risk decreased as iron intake increased, while above it — risk began to rise.
This is an important observation: both iron deficiency and iron excess may be unfavourable, although the mechanisms may differ.
3. Higher sTfR was associated with higher risk, but the result was borderline after full adjustment
The soluble transferrin receptor — sTfR — is a marker of cellular iron demand. In the study, people with kidney stones had higher sTfR values. In the full statistical model, this association was close to statistical significance but did not cross the conventional threshold.
The authors note, however, that in combination with the animal study findings, sTfR may indicate disrupted iron distribution and increased local demand for iron transport in the kidneys.
What did the animal studies show?
In the mouse model of kidney stones, several phenomena were observed:
- greater deposition of calcium deposits in the kidneys,
- higher concentration of Fe²⁺ iron ions in kidney tissue,
- increased expression of transferrin receptor in kidney tubule cells,
- higher levels of lipid peroxidation markers,
- decreased levels of GPX4 and SLC7A11 proteins, which protect cells from ferroptosis.
Ferroptosis is a particular type of cell death dependent on iron and damage to cell membrane lipids. In recent years it has been intensively studied in the context of kidney, liver, neurological and oncological diseases.
In this study, the results suggest that kidneys affected by the stone-forming process may undergo local iron accumulation and activation of ferroptosis. Such a process could damage kidney tubule cells and promote crystal adhesion, and subsequently stone formation.
The paradox: less iron in circulation, more iron locally?
One of the most interesting conclusions drawn by the authors is the hypothesis of an "iron paradox". On one hand, people with kidney stones had lower transferrin saturation, which may suggest reduced iron availability in the circulation. On the other hand, in the animal model the kidneys showed local iron accumulation.
The authors suggest that kidney stones may be associated with chronic inflammation and disrupted iron distribution. Iron may not be properly available in the bloodstream, yet at the same time it may deposit locally in kidney tissue, where it promotes oxidative stress.
This is an interesting hypothesis, but one that still requires confirmation.
What does this mean for people with hemochromatosis?
For patients with hemochromatosis, the study is important primarily because it reveals another possible area in which disrupted iron metabolism may be significant. However, far-reaching conclusions should not be drawn from it.
The study:
- did not analyse patients with hemochromatosis separately,
- did not assess HFE mutations,
- did not examine whether people with high ferritin or classic iron overload have a higher rate of kidney stones,
- does not prove causality.
What can be said, however, is that the paper reinforces the conviction that iron metabolism balance matters for the health of the entire organism, not only for organs traditionally associated with hemochromatosis.
For people with hemochromatosis, the practical message remains sensible: it is worth monitoring iron metabolism parameters and attending to factors that reduce the risk of kidney stones, such as adequate hydration, weight control and metabolic diagnostics in the case of recurrent stones.
Study limitations
The authors themselves highlight several important limitations.
First, the population component was cross-sectional in design. This means the study shows an association between iron parameters and the occurrence of kidney stones, but does not allow one to determine which came first: iron metabolism disorders or kidney stones.
Second, information about kidney stones came from self-reported history, not from a current imaging examination.
Third, the data concerned adult residents of the USA, so the findings require confirmation in other populations.
Fourth, the animal experiments involved small numbers and demonstrate a biological mechanism, but cannot be directly extrapolated to humans.
The key takeaway
The study by Wan and colleagues suggests that iron metabolism disorders may be linked to the risk of kidney stones. In the population analysis, higher iron intake and lower transferrin saturation were associated with a more frequent occurrence of kidney stones. In the animal model of kidney stones, local iron accumulation in the kidneys, oxidative stress and features of ferroptosis were observed.
This is not yet proof that excess iron causes kidney stones. It is, however, an important signal that iron metabolism may participate in the processes leading to kidney damage and stone formation.
For people with hemochromatosis, this is yet another argument to treat iron control as part of broadly understood health prevention — always carried out under medical supervision.
The article was inspired by the work of Wan, W., Yuan, D., Xun, Y., & Yu, X. (2026). Dysregulated iron metabolism and kidney stone risk: an epidemiological and experimental study. Renal Failure, 48(1), 2631316. Accessed online 15.05.2026